Aldevron unveiled Alchemy™ cell-free DNA technology. The technology was designed to support development and preclinical programs, with a future cGMP offering expected to launch in 2025 to ...

FARGO, N.D.--(BUSINESS WIRE)--Aldevron, a global leader in the production of DNA, RNA and protein, has launched its latest innovation, Alchemy™ cell-free DNA technology. This revolutionary ...

In January, Aldevron unveiled its Alchemy cell-free DNA technology. Instead of using cells to produce DNA, Alchemy relies on enzymes to produce linear DNA that serves as a template for the ...

11,12 Here we report the performance of a cell-free DNA (cfDNA) blood-based screening test for colorectal cancer in an average-risk population. The ECLIPSE (Evaluation of the ctDNA LUNAR Test in ...

Lo’s discovery marked a new avenue of inquiry, and over the next 14 years, others confirmed his findings, methods were developed for the analysis of cell-free DNA (cfDNA) to identify fetal ...

A cell-free DNA (cfDNA) blood test, aimed at detecting abnormal DNA signals in people with an average risk of colorectal cancer (CRC), correctly detected CRC in most people confirmed to have the ...

Continued innovation of proprietary cell-free cloning technology has improved synthesis success rates, enabling pricing as low as $0.15 per base pair. SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen ...

Extracellular DNA in blood has emerged as a minimally invasive biomarker for detecting disease. Apart from sequencing cell-free DNA fragments, researchers can also obtain information about methylation ...

We don't have these kinds of studies for the new blood testing, which is called cell-free DNA testing. For the new cell-free DNA testing, a small amount of a person's blood is tested for a large ...

This so-called cell free DNA can be used to identify cancer at very early stages. In a breakthrough, scientists have now developed a method for detecting small amounts of cell-free RNA. When a cell is ...

The global cell-free fetal DNA testing market is experiencing robust growth, with revenue projected to climb from USD 1,566.0 million in 2024 to USD 3,051.5 million by 2035, advancing at a CAGR of 6.1 ...

Donor-derived cell-free DNA can aid detection, diagnosis, and monitoring of antibody-mediated rejection after kidney transplantation. Donor-derived cell-free DNA (dd-cfDNA) is a non-invasive ...